What is TELO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TELO?

P/E (TTM) is n/a and 52-week range is $0.79 to $1.58 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TELO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TELO?

The company profile lists net income (TTM) near -$11M, EPS (TTM) near -$0.15 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Telomir Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Miami, Florida, US, 73.6M shares outstanding, ISIN US87975F1049 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Telomir Pharmaceuticals Inc

$TELO

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Miami, Florida. The company went IPO on 2024-02-09. The firm's lead candidate, Telomir-1 (Telomir-Zn), is an investigational therapy that has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, epigenetic regulation, mitochondrial function, and genomic stability. Telomir-1 is an oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease, and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer’s disease.

Website

telomirpharma.com/

IPO

2024-02-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)